Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from EBOS Group Limited ( (NZ:EBO) ).
EBOS Group Limited has disclosed a change in its capital structure following the lapse of certain performance rights listed on the ASX as EBOAA. The cessation relates to 5,116 performance rights that have expired because the conditions attached to these conditional rights were not met or became incapable of being satisfied as of 1 May 2026.
The announcement, lodged on 6 May 2026 as a new filing, confirms that these securities have ceased and therefore will not convert into ordinary shares. This adjustment marginally reduces the pool of potential equity dilution for existing shareholders, reflecting an outcome in the company’s performance-based incentive arrangements rather than a cash transaction or operational shift.
More about EBOS Group Limited
EBOS Group Limited is a healthcare and pharmaceutical products company listed on the ASX under the code EBO. The group operates across the broader healthcare sector, supplying medicines and related products and services to pharmacies, hospitals and other healthcare providers in Australia and New Zealand, and is a significant distributor within these markets.
For an in-depth examination of EBO stock, go to TipRanks’ Overview page.